Day One Biopharmaceuticals

Paediatric-first oncology company whose tovorafenib became the first targeted therapy for childhood low-grade glioma.

Ojemda (tovorafenib) US approval 2024; Ipsen holds ex-US rights; LOGGIPY-2 first-line phase 3; pimasertib (MEK) combinations.

Headquarters

Brisbane, CA, US

Type

biotech · DAWN

Website

Products

Tovorafenib is a pill for the most common childhood brain tumour, low-grade glioma driven by BRAF changes, approved in 2024.